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Abstract
Background: Two unfortunate outcomes for patients treated surgically for rectal cancer are
placement of a permanent colostomy and local tumor recurrence. Total mesorectal excision is a
new technique for rectal cancer surgery that can lead to improved patient outcomes. We describe
a cluster randomized controlled trial that is testing if the above patient outcomes can be improved
through a knowledge translation strategy called the Quality Initiative in Rectal Cancer (QIRC)
strategy. The strategy is designed to optimize the use of total mesorectal excision techniques.
Methods and Design: Hospitals were randomized to the QIRC strategy (experimental group)
versus normal practice environment (control group). Participating hospitals, and the respective
surgeon group operating in them, are from Ontario, Canada and have an annual procedure volume
for major rectal cancer resections of 15 or greater. Patients were eligible if they underwent major
rectal surgery for a diagnosis of primary rectal cancer. The surgeon-directed QIRC interventions
included a workshop, use of opinion leaders, operative demonstrations, a post-operative
questionnaire, and, audit and feedback. For an operative demonstration participating surgeons
invited a study team surgeon to assist them with a case of rectal cancer surgery. The intent was to
demonstrate total mesorectal excision techniques. Control arm surgeons received no intervention.
Sample size calculations were two-sided, considered the clustering of data at the hospital level, and
were driven by requirements for the outcome local recurrence. To detect an improvement in local
recurrence from 20% to 8% with confidence we required 16 hospitals and 672 patients – 8 hospitals
and 336 patients in each arm. Outcomes data are collected via chart review for at least 30 months
after surgery. Analyses will use an intention-to-treat principle and will consider the clustering of
data. Data collection will be complete by the end of 2007.
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Discussion: Lower rates of permanent colostomy and local tumour recurrence in the intervention
arm would suggest the QIRC strategy is efficacious. The strategy may act as a template for efforts
to improve surgical quality in other areas and will contribute to knowledge on influencing surgeon
practice.
Trial registration: Current Controlled Trials ISRCTN78363167
Background
Surgical resection of rectal cancer is the cornerstone of cur-
ative therapy. Typically during rectal cancer surgery the
tumour and a contiguous segment of normal bowel are
removed and the bowel tract reestablished. For surgically
treated patients two unfortunate outcomes are permanent
colostomy and local tumor recurrence. For various rea-
sons the operating surgeon may deem it necessary to
remove the rectum and anus rendering the patient
dependent on a permanent colostomy. Local tumor recur-
rence is defined as tumour that recurs in the pelvis near
the previous operative site [1-3]. It is especially feared
since this outcome is usually inoperable and patients, as a
result, can suffer a slow, painful death. This study is testing
if these two important outcomes, rates of permanent
colostomy and local tumour recurrence, can be improved
at the hospital level using the surgeon-directed Quality
Initiative in Rectal Cancer (QIRC) strategy.
Studies on rectal cancer surgery outcomes usually show
that rates of permanent colostomy, local tumour recur-
rence, and even patient survival vary markedly at the sur-
geon, hospital, or region level. For example, among the
regions of Ontario, Canada researchers showed that rates
of permanent colostomy following rectal surgery varied
from 31% to 41% [4]. A study examining local tumour
recurrence among surgeons operating in five hospitals in
Edmonton, Alberta showed that rates varied from 10% to
45% based on surgeon specialty training and procedure
volume [5]. These Canadian results are similar to studies
in Europe [6-8]. The presence of important outcome vari-
ations suggests variation in the quality of delivered sur-
gery.
Total mesorectal excision is a refinement of traditional
surgical techniques that stresses sharp dissection of the
mesorectum – the lymph node-bearing portion of the rec-
tum – with careful autonomic nerve preservation [9-11].
There are a growing number of single institution series
describing improvements in outcomes with the introduc-
tion of total mesorectal excision- in particular local
tumour recurrence rates as low as 5% and permanent
colostomy rates of 10–15% [12-18]. Population based
studies from Europe also detail positive changes when
surgeons in large areas adopt total mesorectal excision
principles [19,20].
Knowledge translation research has identified interven-
tions that may encourage physician behaviour change
such as continuing medical education (e.g., workshops),
use of opinion leaders, and audit and feedback [21-28]. It
is also suggested that multiple interventions are more
effective than single interventions. As well, behaviour
change may be enhanced by using quality improvement
principles such as a participatory and supportive
approach that focuses on the system, not individuals;
breaking processes down into definable steps that are
more readily targeted for improvement; and, decreasing
variation in process steps resulting in improved overall
quality [29-32]. The QIRC strategy integrated such knowl-
edge translation interventions and quality improvement
concepts in an attempt to ensure that hospitals (i.e., the
surgeons in the respective hospital) delivered optimal
total mesorectal excision-type surgery to patients.
The purpose of this paper is to describe the methodology
of our cluster randomized controlled QIRC trial, which is
testing if the surgeon-directed QIRC strategy can improve
patient outcomes at the hospital (i.e., cluster) level. We
used a cluster design to minimize the chances of contam-
ination at the patient and surgeon level. We surmised that
patient-level randomization would not work since sur-
geons exposed to new information or techniques, such as
those promoted through the QIRC strategy, would accept
or reject such information or techniques for all of their
subsequent patients. We surmised that surgeon-level ran-
domization would not work since surgeons in a given
hospital often share operative experiences through discus-
sion or direct observation, and thus new information or
techniques would likely be shared among surgeons in a
given hospital. Since surgeons in Ontario rarely perform
rectal cancer surgery at more than one hospital, we were
confident that hospital-level cluster randomization would
minimize the chances of contamination between the two
arms of the QIRC trial.
Methods and Design
Study design
This study is a cluster randomized controlled trial with
hospitals being the clusters. Hospitals were randomized
to the QIRC strategy (intervention group) versus normal
practice environment (control group). The QIRC strategy
is directed at surgeons in hospitals randomized to the
intervention group using a 1:1 allocation ratio.BMC Surgery 2008, 8:4 http://www.biomedcentral.com/1471-2482/8/4
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Participants
Hospitals
To avoid targeting sites with minimal procedure volumes,
we stated that participating hospitals in Ontario, and the
respective surgeon group operating in them, must have an
annual procedure volume for major rectal cancer resec-
tions of 15 or greater. We identified 33 such hospitals
using administrative data for the period April 1, 2000 to
March 31, 2001. Hospitals were then excluded if they had
participated in the QIRC pilot study [33] (3 sites), if the
majority of rectal surgery was performed using laparo-
scopic techniques (2 sites), or if surgeons at the site were
involved in the QIRC trial as rectal surgery experts (4
sites). These two latter criteria were needed since a key
intervention of the QIRC strategy was operative demon-
strations delivered by rectal surgery experts using open
versus laparoscopic techniques (See Interventions below).
Nine hospitals were excluded leaving 24 potential sites.
Hospitals were then eligible if 60% or more of surgeons at
the respective site consented to participate and if the
respective research ethics board approved the study. Sam-
ple size calculations indicated the need for 16 sites. For
the first 18 hospitals approached, nearly every surgeon
consented to participate and 16 hospital ethics boards
approved the study protocol. (Figure 1)
Patients
Patients were eligible if they underwent major rectal can-
cer surgery (i.e., partial or complete segmental resection of
rectum with or without an anastamosis) for a diagnosis of
primary rectal cancer. Thus patients who received local
excisions were not eligible. We defined a rectal versus
colon cancer as a tumour located within 15 cm of the anal
verge by rigid sigmoidoscopy, or, a tumour at or below the
level of the sacral promontory as seen at the time of sur-
gery. These anatomic landmarks ensured the inclusion of
patients that would potentially benefit from total mes-
orectal excision -type surgery. Tumour stage was not used
as an exclusion criterion since issues of permanent colos-
tomy and local recurrence are relevant to all patients
undergoing surgery.
Intervention
The QIRC strategy is a set of interventions directed at sur-
geons working in a given hospital. The interventions
include: a workshop, use of opinion leaders, operative
demonstrations, a post-operative questionnaire, as well as
audit and feedback.
Workshops
These were used to introduce to participating surgeons all
aspects of the study and new information. For the latter,
topics included rectal cancer surgery outcomes in Ontario
and elsewhere, total mesorectal excision, and, knowledge
translation and quality improvement. The intent of the
workshop was to promote thought in three areas: 1) There
is a need to improve population level rectal cancer surgery
outcomes in most jurisdictions. 2) The QIRC strategy may
help surgeons improve these outcomes. 3) The pursuit of
surgical excellence is an active and continuous process.
Opinion leaders
At each workshop, participating surgeons selected an
opinion leader for their hospital using a validated
approach [34]. In summary, the selection was based on
the opinion leader having three attributes including a
high level of clinical expertise, a willingness to share
knowledge, and being educationally influential. The
opinion leader acted as a local resource person on issues
pertinent to the study. For example, the opinion leader
encouraged their colleagues to participate in operative
demonstrations.
Operative demonstration
Participating surgeons invited a study team surgeon to
assist them with a case of rectal cancer surgery. The main
intent was to demonstrate total mesorectal excision tech-
niques. Surgeons were encouraged to participate in a min-
imum of two operative demonstrations. The participating
QIRC trial schema Figure 1
QIRC trial schema.
 
 
33 Ontario hospitals with an annual procedure volume for major rectal cancer 
resections of > 15 for the period April 1, 2000 to March 31, 2001 
Approached 18 hospitals to participate 
Assessed for eligibility: 
•  60% or more of surgeons at the respective site consented to participate  
•  Research Ethics Board approval 
Excluded: 
Research Ethics Board denied approval 
(2 hospitals) 
Randomized 16 hospitals 
Allocated to intervention (8 hospitals) 
Received QIRC strategy: 
•  Workshop 
•  Opinion leader 
•  Operative demonstration 
•  Post-operative questionnaire 
•  Audit & feedback 
Allocated to control (8 hospitals) 
Usual practice environment, i.e., onus is on 
the individual surgeon to obtain new 
knowledge or skills for any aspect of the care 
they provide 
 
 
Excluded: 
•  Participated in the QIRC pilot study (3 hospitals) 
•  Majority of rectal cancer surgery performed 
laparoscopically (2 hospitals) 
•  Surgeons at the hospital involved in the QIRC trial as 
rectal surgery experts (4 hospitals) 
24 hospitals BMC Surgery 2008, 8:4 http://www.biomedcentral.com/1471-2482/8/4
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surgeon retained full control over all peri-operative and
operative decision-making.
Operative questionnaire
This questionnaire was completed after each rectal cancer
surgery. The questions were designed to prompt surgeons
to re-examine key total mesorectal excision operative steps
[see Additional file 1].
Audit and feedback
Data (e.g., rates of permanent colostomy) were provided
to individual surgeons and in a group forum for overall
hospital results. The intent of feedback was to encourage
individual surgeons to constantly self-examine surgical
decision-making.
Control arm
Hospitals in the control group represented the normal
environment where the onus is on the individual surgeon
to obtain new knowledge or skills for any aspect of the
care they provide. Efforts to improve the quality of rectal
cancer care among control arm surgeons were not facili-
tated by the study team.
Objectives
Primary objective
We wish to test the efficacy of the QIRC strategy to
improve hospital rates of permanent colostomy and local
tumour recurrence among patients surgically treated for
rectal cancer. We hypothesize that hospitals exposed to
the QIRC strategy (intervention) will have better out-
comes – lower rates of permanent colostomy and local
tumour recurrence – compared to hospitals in the normal
practice environment (control).
Secondary objective
We wish to test if the QIRC strategy can lead to improved
quality of life, and improved bladder, bowel, and sexual
function among patients surgically treated for rectal can-
cer. We hypothesize that patients treated in hospitals
exposed to the QIRC strategy (intervention) will have
higher scores on quality of life measures, and bowel, blad-
der and sexual function questionnaires compared to
patients treated in control arm hospitals.
Outcome measures
Primary outcomes
Since the hospital is our unit of analysis it is imperative
that consecutive patients be included to prevent surgeon
selection bias (e.g., excluding patients with difficult
tumours perceived as high-risk for negative outcomes).
Three methods of patient accrual were used to ensure con-
secutive patient accrual for primary outcomes – regular
(weekly) phone calls to surgeons' offices, review of oper-
ating room booking logs, and hospital health records que-
ries. Patient consent was not obtained for primary
outcomes since data were collected via retrospective chart
review and involved no patient contact. Primary out-
comes included:
Hospital rate of permanent colostomy
It is usually known at the time of rectal cancer surgery if a
person has received a permanent colostomy. However, in
cases where a patient receives a temporary stoma 18
months will be allowed for temporary stoma closure, after
which time the patient will be designated as having a per-
manent colostomy. An anastomosis of the rectum must
also be functioning for at least three months to be consid-
ered a non-permanent colostomy. This will prevent a pos-
itive outcome being marked for a patient who
subsequently receives a colostomy for problems such as
an anastomotic leak or severe incontinence.
Hospital rate of local recurrence
Local tumor recurrence is usually defined as tumour that
recurs in the pelvis near the previous operative site [1-3].
Most, though not all, local recurrences manifest within
two years of surgery. In this study local recurrence in the
pelvis will be defined in three ways:
1. Definite recurrence – positive histology.
2. Probable recurrence – a postoperative mass in the area
of previous pelvic surgery with any of the following
patient signs (hydronephrosis, invasion of pelvic struc-
tures, or bleeding rectal mass) or symptoms (deteriorating
sexual function, deteriorating bladder function, deterio-
rating bowel function, or persistent and worsening lower
back, perineal or sciatic pain).
3. Possible recurrence – based strictly on a patient devel-
oping any of the symptoms mentioned above (deteriorat-
ing sexual function, deteriorating bladder function,
deteriorating bowel function, or persistent and worsening
lower back, perineal or sciatic pain).
Secondary outcomes
Surgeons determined which of their respective patients
may be candidates to participate in secondary outcomes
data collection. Surgeons introduced this part of the study
to appropriate patients and if the individual was agreea-
ble, the study team approached the respective patient to
obtain written informed consent. Patients were not
approached if they were too ill, frail or psychologically
vulnerable, as determined by the participating surgeon.
Patients required sufficient command of the English lan-
guage and capacity to give informed consent. Secondary
outcomes included:BMC Surgery 2008, 8:4 http://www.biomedcentral.com/1471-2482/8/4
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Quality of life
To assess overall impact of disease and treatment on
patient quality of life we used the following: the European
Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30 [35], an instrument to assess quality
of life in cancer patients; the supplemental EORTC QLQ-
CR38 [36], a colorectal cancer-specific quality of life ques-
tionnaire module; and, the 36-Item Short Form Health
Survey, Version 2 (SF-36) [37].
Bowel, bladder and sexual function
At the time of trial initiation we felt there was no validated
instrument(s) that adequately addressed these three
important domains. To this end a brief set of questions
were developed [see Additional file 2].
Sample size
We calculated the intracluster correlation coefficient using
the a priori variation in permanent colostomy rates
among hospitals in Ontario with a rectal cancer procedure
volume of at least 15 per year for years 1997 to 1999
(Intracluster correlation = 0.4) [38,39]. We used a con-
servative spectrum of values for local recurrence intraclass
correlation coefficients. Alpha and beta were set at 0.05
and 0.2, respectively. Tests were two-sided and assumed
that a clinically important change would consist of
decrease in the baseline rate of permanent colostomy
from 30% to 15%. Using permanent colostomy as the
outcome, the study required 8 hospitals and 311 patients
in each arm. For local recurrence we extrapolated from the
literature, and assumed that local recurrence rates are a
conservative 20% and can be brought down to 8% in the
intervention arm. To detect this difference with confi-
dence we required 16 hospitals and 672 patients – 8 hos-
pitals and 336 patients in each arm. Thus, the sample size
required for the outcome local recurrence determined our
final sample size requirements. We randomized 16 hospi-
tals and anticipated an accrual period of 24 months.
Randomization
The study statistician generated and administered a
blocked 1:1 allocation randomization arrangement for
the 16 study hospitals. We did not stratify hospitals by
procedure-volume or teaching status since previous
research in Ontario indicates that such hospital character-
istics do not differentiate patient outcomes following
colorectal cancer surgery [40,41]. Following the randomi-
zation of an intervention arm site, no further hospital was
randomized until that site participated in a workshop (the
first component of the QIRC strategy). This was done
since patients were immediately accrued following site
randomization, despite the typical requirement of 2–4
weeks to arrange a workshop with all or at least a majority
of the surgeons at the respective site.
Data gathering
Data are being collected for patients in the intervention
and control groups in identical ways. Primary outcomes
data are collected via chart review for at least 30 months,
and thus follow-up will be greater for all but the final
patients enrolled in the trial. This follow-up period will
allow identification of local recurrence events, since local
recurrence typically occurs within two years of surgery [1-
3]. Hospital charts are reviewed within two weeks of sur-
gery and every three months thereafter. Regional Cancer
Centre charts are also reviewed to optimize the collection
of data on potential patient treatments (e.g., radiation
therapy) and outcomes (e.g., local recurrence). In
Ontario, all radiation therapy is delivered at a small
number of such Cancer Centres. Quality of life and bowel,
bladder, and sexual function were measured at four times:
baseline (pre-operatively or within 4 weeks of surgery)
and at 6, 12 and 18 months post-surgery. Trained asses-
sors obtained data for secondary outcomes during tele-
phone interviews. All data will be handled with strict
confidentiality, and study reports or presentations will
maintain patient, surgeon, and hospital anonymity. Data
collection will be complete by the end of 2007.
Analysis
We will use the intention-to-treat principle to analyse
data. We will use multiple imputation to handle missing
data [42]. Treatment arms will be compared with respect
to potential covariates using continuous and categorical
univariable analyses. This will include patient (age, sex,
comorbidities, weight and height), treatment (adjuvant
therapies), tumour (stage, node counts, margin status,
other histology measures), and hospital (teaching status,
procedure volume) level variables. Methods of analysis,
including adjustment for covariates, will use the cluster
randomization trial design [38,39]. Specifically, the pri-
mary outcomes of colostomy rate and local recurrence
rate will be assessed using a nested (cluster) analysis
model that will consider the correlation of outcomes
within each hospital, and the influence of covariables.
Adjustments for adjuvant therapies are especially impor-
tant since it is likely these treatments will not be delivered
among centers using a standard regimen. The major
design factor will be arm of study (experimental or con-
trol). No adjustment will be made for multiple compari-
sons of primary outcomes since each is of interest on its
own. Secondary analyses will be conducted on bowel,
bladder and sexual function, and quality of life using
nested analysis of variance. We will conduct analyses
using the latest versions of SAS, SPlus and StatXact soft-
ware as needed. The trial will be reported according to the
CONSORT standards for reporting cluster-randomized
trials [43]. The results will be expressed as odds ratio [OR]
(for binary outcomes), hazard ratio [HR] (for time-to-
event outcomes) or mean difference (for continuous out-BMC Surgery 2008, 8:4 http://www.biomedcentral.com/1471-2482/8/4
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comes), with corresponding standard errors, 95% confi-
dence intervals and associated p-values. P-values will be
reported to three decimal places with p-values less than
0.001 reported as p < 0.001. For all tests, we will use alpha
= 0.05 level of significance. We will examine residuals to
assess goodness-of-fit and model assumptions for all anal-
yses as appropriate.
Nested studies
Surgeon survey
At the completion of accrual surgeons were mailed a sur-
vey. Intervention arm surgeons were asked to comment
on their involvement in the trial, to evaluate the individ-
ual QIRC strategy interventions and the overall strategy,
and to provide insights on issues that may be relevant to
the uptake of a new innovation such as the QIRC strategy.
A similar survey was sent to control arm surgeons, how-
ever, they were not asked to evaluate the individual QIRC
strategy interventions. Participation in the survey was vol-
untary. Surgeons who agreed to participate were given the
option to identify themselves or remain anonymous.
Qualitative interviews
Qualitative telephone interviews were conducted with
opinion leaders in the intervention arm hospitals. At least
one other surgeon from each of the intervention arm hos-
pitals was also interviewed. Participation in the interviews
was voluntary. The interviews will assist in assessing the
role of the local opinion leader and the overall QIRC strat-
egy
Ethics
The study is being conducted according to the established
guidelines of proper conduct of medical research involv-
ing human subjects set by the Tri-council Policy Statement
and the GCP guidelines [44-48]. The Research Ethics
Board (REB) of the Hamilton Health Sciences/McMaster
University approved this protocol (REB project number
01-202). Each participating hospital also provided local
ethics approval prior to enrollment. Ethics approval from
Ontario Regional Cancer Centres was also necessary for
the examination of study patients' charts. Individual sur-
geons provided written consent, as did all patients who
participated in the collection of secondary outcomes data
(i.e., quality of life scores, and questionnaires on bowel,
bladder and sexual function).
Discussion
The QIRC trial will assess if the QIRC strategy, which is
designed to positively influence surgeon practice at a
given hospital, can lead to improved patient outcomes of
rectal cancer surgery. Lower permanent colostomy and
local tumour recurrence rates in the intervention arm
would suggest that the QIRC strategy is efficacious. The
strategy may also act as a template for efforts to improve
surgical quality in other cancer sites.
Participants in a clinical trial may alter – improve – their
behaviour in response to being observed rather than as a
result of a study intervention [49,50]. This phenomenon
is known as the Hawthorne effect and it is important to
consider in trials designed to influence physician behav-
iour and action. Surgeons in both arms of the QIRC trial
may be subject to a potential Hawthorne effect. Surgeons
in the control arm will consent to randomization and be
cognizant of ongoing data abstraction. In addition to
these maneuvers, surgeons in the experimental arm will
receive the QIRC strategy. Thus, all surgeons in the study
will be aware their actions are being observed. Any
improvement in patient outcomes in the experimental
arm must be above and beyond the Hawthorne effect, and
would be attributed to the intervention.
We are aware of one other trial that tested if knowledge
translation or quality improvement methods could influ-
ence (i.e., improve) surgeon practice [51]. This trial used
continuing medical education and opinion leaders to
improve (i.e., lower) rates of cesarean section. The rela-
tively small number of randomized trials that involve sur-
geons usually compare the delivery of contrasting
treatments (e.g., surgical versus medical therapy for
patients with carotid stenosis, or, different methods of
surgically treating patients with breast cancer). Thus,
regardless of our results, successful engagement of sur-
geon participation in this cluster-randomized trial will be
an important observation in and of itself. This trial does
not compare total mesorectal excision-type surgery versus
standard surgery, rather it is comparing a strategy
designed to influence surgeon practice versus the normal
environment. Thus, the trial will contribute greatly to
knowledge on optimizing surgeon practice.
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